Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis

Author(s): Karl Vass .

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 29 , 2012

Abstract:

Autoimmune diseases of the nervous system such as myasthenia gravis, inflammatory demyelinating polyneuropathies, multiple sclerosis and others are still not curable. Yet the introduction of modern immune therapies could significantly improve the prospects of many patients affected by these disorders. In addition to steroids and immunosuppression i.v. immunoglobulins are used for treatment of myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Interferons, glatiramer acetate, natalizumab and fingolimod are applied in multiple sclerosis. The ever-improving efficacy of the drugs has to be balanced against the increasing risk of possible severe adverse effects.

Keywords: Nervous system, autoimmune disease, myasthenia gravis, inflammatory demyelinating polyneuropathy, multiple sclerosis, interferon, glatiramerazetat, natalizumab, fingolimod, drugs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 29
Year: 2012
Page: [4513 - 4517]
Pages: 5
DOI: 10.2174/138161212802502288
Price: $58

Article Metrics

PDF: 12